The FDA accepted an investigational new drug application for a trispecific fusion antibody for the treatment of diabetic macular edema, according to a press release from Eluminex Biosciences.
EB-105 targets VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 (IL-6) receptor for the treatment of DME.
In the release, Quan Dong Nguyen, MD, MSc, FARVO, FASRS, said elevated levels of IL-6 are well documented in patients with DME and can contribute to inflammation and vascular permeability in other retinal diseases such as neovascular age-related macular degeneration.
“High